GEORGIA HOSPITAL HEALTH SERVICE & CLASS ACTION CAPITAL PARTNERSHIP PORTAL

Georgia Hospital Health Services (GHHS), a wholly owned subsidiary of the Georgia Hospital Association, has partnered with Class Action Capital, a market leader in class action settlement claim management.

Class Action Capital is already successfully working with a very large number of hospitals, healthcare facilities, and state hospital associations across the country helping to recover meaningful refunds on their behalf from a number of recent class action settlements.

Many healthcare companies do not have the time, resources or relevant data available in order to file a settlement claim. Class Action Capital will work with you in order to submit a fully comprehensive claim recovery, while minimizing the use of your time, internal resources and the risk of mistake if you were to take on claims management on your own.

MultiPlan Health Ins. Provider Litigation

According to the complaint, MultiPlan is a company that helps health insurers underpay struggling healthcare providers. It started as a company that sold nationwide “wrap” networks of contracted providers to insurance companies, so that insurers could supplement their own networks available to members of the insurers’ Preferred Provider Organization (“PPO”) insurance plans.

Over the past decade, MultiPlan has mutated into a company that offers what it calls “claims repricing” services to address the bills insurers receive when a member receives care not covered by the insurer’s preferred network. “Claims repricing” is a misnomer: what MultiPlan’s services actually do—what they are designed to do—is suppress and fix the prices insurers pay physicians for “out-of-network” medical care. Any time the word “repricing” is used to describe MultiPlan’s services, it should be understood to mean “price-fixing.

All healthcare providers that were paid for out-of-network healthcare services by any commercial third-party payer, including but not limited to the Defendants, pursuant to MultiPlan’s claims repricing services from January 1, 2015 through the present are likely eligible.

Generic Pharmaceuticals Class Actions

This large, multidistrict litigation involved allegations that numerous generic drug manufacturers conspired to artificially inflate prices and reduce competition for various generic medications.

The “Indirect Reseller” case alleges that the major manufacturers of generic drugs colluded to fix the cost of them dating back to 2010 (class period varies by drug). The indirect reseller class further alleges that the major distributors (with an 81% market share) colluded with manufacturers to pass the cost down to independent pharmacies and hospitals.

The “End Payer” class allege that Defendants engaged in an unlawful scheme or schemes to fix, maintain and stabilize prices, rig bids, and engage in market and customer allocation of the Named Generic Drugs in violation of federal and state antitrust laws, consumer protection statutes and common law. EPPs allege that Defendants’ conduct harmed competition and caused Settlement Class Members to overpay for the Named Generic Drugs. The current settlement fund is approximately $503 million.